Back to Search
Start Over
Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Mar 23; Vol. 12, pp. 631662. Date of Electronic Publication: 2021 Mar 23 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: This prospective multicenter study developed an integrative clinical and molecular longitudinal study in Rheumatoid Arthritis (RA) patients to explore changes in serologic parameters following anti-TNF therapy (TNF inhibitors, TNFi) and built on machine-learning algorithms aimed at the prediction of TNFi response, based on clinical and molecular profiles of RA patients. Methods: A total of 104 RA patients from two independent cohorts undergoing TNFi and 29 healthy donors (HD) were enrolled for the discovery and validation of prediction biomarkers. Serum samples were obtained at baseline and 6 months after treatment, and therapeutic efficacy was evaluated. Serum inflammatory profile, oxidative stress markers and NETosis-derived bioproducts were quantified and miRNomes were recognized by next-generation sequencing. Then, clinical and molecular changes induced by TNFi were delineated. Clinical and molecular signatures predictors of clinical response were assessed with supervised machine learning methods, using regularized logistic regressions. Results: Altered inflammatory, oxidative and NETosis-derived biomolecules were found in RA patients vs. HD, closely interconnected and associated with specific miRNA profiles. This altered molecular profile allowed the unsupervised division of three clusters of RA patients, showing distinctive clinical phenotypes, further linked to the TNFi effectiveness. Moreover, TNFi treatment reversed the molecular alterations in parallel to the clinical outcome. Machine-learning algorithms in the discovery cohort identified both, clinical and molecular signatures as potential predictors of response to TNFi treatment with high accuracy, which was further increased when both features were integrated in a mixed model (AUC: 0.91). These results were confirmed in the validation cohort. Conclusions: Our overall data suggest that: 1. RA patients undergoing anti-TNF-therapy conform distinctive clusters based on altered molecular profiles, which are directly linked to their clinical status at baseline. 2. Clinical effectiveness of anti-TNF therapy was divergent among these molecular clusters and associated with a specific modulation of the inflammatory response, the reestablishment of the altered oxidative status, the reduction of NETosis, and the reversion of related altered miRNAs. 3. The integrative analysis of the clinical and molecular profiles using machine learning allows the identification of novel signatures as potential predictors of therapeutic response to TNFi therapy.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Luque-Tévar, Perez-Sanchez, Patiño-Trives, Barbarroja, Arias de la Rosa, Abalos-Aguilera, Marin-Sanz, Ruiz-Vilchez, Ortega-Castro, Font, Lopez-Medina, Romero-Gomez, Rodriguez-Escalera, Perez-Venegas, Ruiz-Montesinos, Dominguez, Romero-Barco, Fernandez-Nebro, Mena-Vazquez, Marenco, Uceda-Montañez, Toledo-Coello, Aguirre, Escudero-Contreras, Collantes-Estevez and Lopez-Pedrera.)
- Subjects :
- Adult
Arthritis, Rheumatoid classification
Arthritis, Rheumatoid diagnosis
Biomarkers blood
Cluster Analysis
Extracellular Traps metabolism
Female
Humans
Inflammation
Longitudinal Studies
Machine Learning
Male
MicroRNAs blood
Middle Aged
Oxidative Stress
Phenotype
Predictive Value of Tests
Prospective Studies
Treatment Outcome
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid blood
Arthritis, Rheumatoid drug therapy
Tumor Necrosis Factor Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33833756
- Full Text :
- https://doi.org/10.3389/fimmu.2021.631662